4.6 Article

Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function

Journal

PLOS ONE
Volume 9, Issue 4, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0096260

Keywords

-

Funding

  1. Parkinson's UK Innovation Grant [K-1006]
  2. National Institute of Health Research Academic Clinical Fellowship
  3. PSP Association
  4. Weston Trust-Reta Lila Howard Foundation
  5. Novartis
  6. Teva
  7. Meda
  8. Boehringer Ingelheim
  9. GSK
  10. Ipsen
  11. Lundbeck
  12. Allergan
  13. Orion
  14. BIAL
  15. Noscira
  16. Roche
  17. Merck-Serono
  18. Biogen-Idec
  19. Ironwood
  20. Genentech
  21. Sanofi-Aventis
  22. UCB Pharmaceuticals
  23. Vertex
  24. Eisai
  25. Elan
  26. Fiveprime
  27. Bayer-Schering
  28. Synthon BV
  29. Genyme
  30. GW Pharma
  31. Merz

Ask authors/readers for more resources

Background: The Bradykinesia Akinesia Incoordination (BRAIN) test is a computer keyboard-tapping task that was developed for use in assessing the effect of symptomatic treatment on motor function in Parkinson's disease (PD). An online version has now been designed for use in a wider clinical context and the research setting. Methods: Validation of the online BRAIN test was undertaken in 58 patients with Parkinson's disease (PD) and 93 age-matched, non-neurological controls. Kinesia scores (KS30, number of key taps in 30 seconds), akinesia times (AT30, mean dwell time on each key in milliseconds), incoordination scores (IS30, variance of travelling time between key presses) and dysmetria scores (DS30, accuracy of key presses) were compared between groups. These parameters were correlated against total motor scores and sub-scores from the Unified Parkinson's Disease Rating Scale (UPDRS). Results: Mean KS30, AT30 and IS30 were significantly different between PD patients and controls (p <= 0.0001). Sensitivity for 85% specificity was 50% for KS30, 40% for AT30 and 29% for IS30. KS30, AT30 and IS30 correlated significantly with UPDRS total motor scores (r = -0.53, r = 0.27 and r = 0.28 respectively) and motor UPDRS sub-scores. The reliability of KS30, AT30 and DS30 was good on repeated testing. Conclusions: The BRAIN test is a reliable, convenient test of upper limb motor function that can be used routinely in the outpatient clinic, at home and in clinical trials. In addition, it can be used as an objective longitudinal measurement of emerging motor dysfunction for the prediction of PD in at-risk cohorts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available